002422 科伦药业
已收盘 05-26 15:00:00
资讯
新帖
简况
董事长大秀肌肉难阻公司业绩收缩,科伦系“三驾马车”全面失速
蓝鲸财经 · 12:04
董事长大秀肌肉难阻公司业绩收缩,科伦系“三驾马车”全面失速
默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼
金吾财讯 · 05-22
默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼
科伦药业(002422)披露子公司在ASCO年会公布多项创新药物研究成果,5月22日股价上涨7.19%
中金财经 · 05-22
科伦药业(002422)披露子公司在ASCO年会公布多项创新药物研究成果,5月22日股价上涨7.19%
5月22日科伦药业涨7.19%,中欧医疗健康混合A基金重仓该股
证券之星 · 05-22
5月22日科伦药业涨7.19%,中欧医疗健康混合A基金重仓该股
科伦药业涨7.19%,东海证券一个月前给出“买入”评级
证券之星 · 05-22
科伦药业涨7.19%,东海证券一个月前给出“买入”评级
科伦博泰生物:肺癌三期试验显示,Sacituzumab Tirumotecan联合帕博利珠单抗显著延长无进展生存期
美股速递 · 05-22
科伦博泰生物:肺癌三期试验显示,Sacituzumab Tirumotecan联合帕博利珠单抗显著延长无进展生存期
科伦药业(002422)披露控股股东部分股份质押及解除质押公告,5月21日股价上涨1.35%
证券之星 · 05-21
科伦药业(002422)披露控股股东部分股份质押及解除质押公告,5月21日股价上涨1.35%
科伦药业涨5.58%,东海证券一个月前给出“买入”评级
证券之星 · 05-19
科伦药业涨5.58%,东海证券一个月前给出“买入”评级
科伦药业:公司股份回购计划将严格按照相关规则依规履行实施
证券之星 · 05-18
科伦药业:公司股份回购计划将严格按照相关规则依规履行实施
科伦药业(002422.SZ)子公司SKB118新药临床试验申请获批
智通财经 · 05-13
科伦药业(002422.SZ)子公司SKB118新药临床试验申请获批
科伦药业陷入“三重承压”:旧引擎熄火,新故事难讲,百亿营收保卫战打响
新浪证券 · 05-09
科伦药业陷入“三重承压”:旧引擎熄火,新故事难讲,百亿营收保卫战打响
科伦药业(002422)披露回购股份价格上限调整公告,5月6日股价下跌1.62%
证券之星 · 05-06
科伦药业(002422)披露回购股份价格上限调整公告,5月6日股价下跌1.62%
科伦药业(002422)披露控股股东部分股份质押及解除质押公告,4月29日股价上涨4.6%
证券之星 · 04-29
科伦药业(002422)披露控股股东部分股份质押及解除质押公告,4月29日股价上涨4.6%
图解科伦药业一季报:第一季度单季净利润同比下降22.34%
证券之星 · 04-29
图解科伦药业一季报:第一季度单季净利润同比下降22.34%
科伦药业:公司持有海南普利制药股份有限公司股权
证券之星 · 04-20
科伦药业:公司持有海南普利制药股份有限公司股权
股市必读:科伦药业(002422)4月16日董秘有最新回复
证券之星 · 04-17
股市必读:科伦药业(002422)4月16日董秘有最新回复
科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权
证券之星 · 04-15
科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权
股市必读:科伦药业(002422)4月13日董秘有最新回复
证券之星 · 04-14
股市必读:科伦药业(002422)4月13日董秘有最新回复
4月9日科伦药业发布公告,股东减持318.21万股
证券之星 · 04-09
4月9日科伦药业发布公告,股东减持318.21万股
科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?
新浪证券 · 04-09
科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?
加载更多
公司概况
公司名称:
四川科伦药业股份有限公司
所属行业:
医药制造业
上市日期:
2010-06-03
主营业务:
四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。
发行价格:
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":35.23,"timestamp":1779778986000,"preClose":34.36,"halted":0,"volume":22820756,"delay":0,"changeRate":0.0253,"floatShares":1299000000,"shares":1591000000,"eps":0.9879,"marketStatus":"已收盘","change":0.87,"latestTime":"05-26 15:00:00","open":34.36,"high":35.89,"low":34.2,"amount":807000000,"amplitude":0.0492,"askPrice":35.3,"askSize":12,"bidPrice":35.23,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.9879,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":5,"adr":0,"adjPreClose":34.36,"symbolType":"stock","openAndCloseTimeList":[[1779759000000,1779766200000],[1779771600000,1779778800000]],"highLimit":37.8,"lowLimit":30.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1590781208,"isCdr":false,"pbRate":2.22,"roa":"--","peRate":35.661504,"roe":"1.86%","epsLYR":1.07,"committee":-0.489209,"marketValue":56043000000,"turnoverRate":0.0176,"status":0,"floatMarketCap":45750000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2638064567","title":"董事长大秀肌肉难阻公司业绩收缩,科伦系“三驾马车”全面失速","url":"https://stock-news.laohu8.com/highlight/detail?id=2638064567","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638064567?lang=zh_cn&edition=full","pubTime":"2026-05-26 12:04","pubTimestamp":1779768249,"startTime":"0","endTime":"0","summary":"“三驾马车”全面失速根据科伦药业2025年年度报告,公司全年实现营业总收入185.13亿元,同比下降15.13%;归属于上市公司股东的净利润17.02亿元,同比大幅下滑42.03%;扣除非经常性损益后净利润15.97亿元,同比下降44.99%,为近五年来首次营收、净利双降。科伦系另一家A股上市公司业绩同样不乐观。2026年起科伦系有望迎来边际修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779766804153183417","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","LU1934453819.USD","LU1064131003.USD","LU1979443071.USD","BK1161","002422","LU0196878994.USD","BK0060","LU1064130708.USD","LU2148510915.USD","06990","MSD","301301"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637531064","title":"默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2637531064","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637531064?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:14","pubTimestamp":1779459290,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦生物周四披露重要临床进展,企业与默沙东合作研发的抗体药物偶联物,相关疗法在晚期肺癌临床试验中,疗效表现超越常规抗 PD-1 治疗方案。公开试验摘要显示,默沙东 2022 年取得大中华区以外权益的 sac-TMT,可显著降低 65% 疾病进展与死亡风险,数据具备统计学价值。安全性层面两组差异明显,联合用药重度不良反应发生率为 55%,单药组仅 31%。两类药物停药相关不良反应占比分别为 4% 与 5%,单药停药比例同样为 5%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"热榜No.54 · 默沙东与科伦博泰联合研发肺癌新疗法III期试验成功","theme_type":2,"isJumpTheme":false,"source_url":"300749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU1699723380.USD","LU2491050154.USD","LU2461242641.AUD","LU1116320737.USD","LU1934455194.USD","LU2125909247.SGD","LU0980610538.SGD","BK4516","SG9999002224.SGD","SG9999015341.SGD","LU2491050071.SGD","LU2106854487.HKD","LU2433249047.HKD","LU0868494617.USD","LU2361045086.USD","LU0265550946.USD","LU1923622614.USD","SG9999014567.USD","IE0002141913.USD","IE00BBT3K403.USD","LU1941712348.USD","SG9999001176.SGD","LU0130102774.USD","LU1093756168.USD","LU1093756325.SGD","LU2361044949.HKD","LU2023250843.SGD","LU0965509010.AUD","LU0211331839.USD","LU1201861249.SGD","LU0122379950.USD","LU2125154778.USD","LU1023059063.AUD","LU2112291526.USD","BK4007","BK4585","IE00BSNM7G36.USD","LU1979443071.USD","LU0868494708.USD","LU1934455863.HKD","LU0861579265.USD","LU1064131003.USD","LU1983299246.USD","LU1064130708.USD","LU1585245621.USD","LU0058720904.USD","LU0006306889.USD","LU0070302665.USD","IE00BLSP4452.SGD","LU1037948897.HKD","LU1989772923.USD","BK0060","LU0098860793.USD","LU1035773651.USD","LU1291159041.SGD","LU1116320901.HKD","LU1934455277.USD","LU1066053197.SGD","BK4534","SG9999002232.USD","LU2148510915.USD","LU1571399168.USD","SG9999013999.USD","LU0265550359.USD","LU0965509283.SGD","LU1066051225.USD","IE00B2B36J28.USD","SG9999014559.SGD","LU0320765489.SGD","LU1069347547.HKD","LU0203345920.USD","IE00BJT1NW94.SGD","LU2491049909.HKD","LU0985320562.USD","LU2357627491.SGD","LU0965509101.SGD","IE00B4R5TH58.HKD","SG9999014542.SGD","BK4533","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","IE00BN8TJ469.HKD","LU0238689110.USD","LU1929549753.HKD","LU2023250504.SGD","LU0432979614.USD","LU0648001328.SGD","SG9999001176.USD","LU0106261372.USD","LU1974910355.USD","LU1162221912.USD","LU0203347892.USD","BK0239","LU2125154935.USD","IE00B1BXHZ80.USD","LU1934453819.USD","LU2324357040.USD","LU2361044865.SGD","LU0859254822.USD","BK4588","IE00BLSP4239.USD","SG9999001440.SGD","LU0289739699.SGD","LU2125909593.SGD","MRK","LU0234572021.USD","IE0009355771.USD","LU0320765646.SGD","LU1989772840.SGD","002422","BK4550","LU1037948541.HKD","LU1917777945.USD","SG9999014575.USD","LU0942090050.USD","IE000M9KFDE8.USD","LU1057294990.SGD","LU0965508806.USD","LU1989771016.USD","LU1066051498.USD","LU2468319806.SGD","BK4559","SG9999015358.SGD","LU0130517989.USD","SGXZ57979304.SGD","LU0266013472.USD","LU1941712264.USD","LU0477156953.USD","LU2360032135.SGD","LU1066051811.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637133913","title":"科伦药业(002422)披露子公司在ASCO年会公布多项创新药物研究成果,5月22日股价上涨7.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637133913","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637133913?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:03","pubTimestamp":1779444189,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}table{border-collapse:collapse;}table,th,td{border: 1px solid black;}.article_content ul{padding-left:22px;}截至2026年5月22日收盘,科伦药业报收于34.72元,较前一交易日上涨7.19%,最新总市值为552.32亿元。该股当日开盘33.57元,最高35.57元,最低33.57元,成交额达13.46亿元,换手率为2.98%。近日,科伦药业发布公告称,其控股子公司科伦博泰将在2026年美国临床肿瘤学会年会上公布多项创新药物研究成果。两项研究数据支持的相关上市申请已获NMPA受理。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/22/20260522583175.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/22/20260522583175.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260522/32247397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","LU1979443071.USD","LU1064130708.USD","002422","LU2148510915.USD","LU1934453819.USD","BK0060","LU1064131003.USD","BK1574","06978","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637394030","title":"5月22日科伦药业涨7.19%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637394030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637394030?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:38","pubTimestamp":1779439119,"startTime":"0","endTime":"0","summary":"证券之星消息,5月22日科伦药业涨7.19%,收盘报34.72元,换手率2.98%,成交量38.72万手,成交额13.46亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共109家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元,最新净值1.6729,较上一交易日上涨1.05%,近一年上涨2.26%。中欧医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0060","LU1934453819.USD","LU1979443071.USD","002422","LU2148510915.USD","159760","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637394255","title":"科伦药业涨7.19%,东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2637394255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637394255?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:38","pubTimestamp":1779439110,"startTime":"0","endTime":"0","summary":"今日科伦药业涨7.19%,收盘报34.72元。2026年4月15日,东海证券研究员杜永宏,付婷发布了对科伦药业的研报《公司简评报告:传统主业企稳可期,创新商业化快速推进》,该研报对科伦药业给出“买入”评级。公司输液和中间体及原料药业务有望企稳向上,创新产品快速放量,维持“买入”评级。科伦药业个股概况:以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180586961","title":"科伦博泰生物:肺癌三期试验显示,Sacituzumab Tirumotecan联合帕博利珠单抗显著延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1180586961","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180586961?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:04","pubTimestamp":1779397496,"startTime":"0","endTime":"0","summary":"在针对肺癌的第三期临床试验中,科伦博泰生物(SKB BIO)的研究数据显示,其药物Sacituzumab Tirumotecan与帕博利珠单抗(Pembrolizumab)联合治疗方案,相较于单独使用帕博利珠单抗,显著延长了患者的无进展生存期(PFS)。这一积极结果凸显了联合疗法在提升疗效方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","SG9999001440.SGD","LU0965509101.SGD","LU0058720904.USD","SG9999014559.SGD","SG9999015358.SGD","SG9999015341.SGD","LU1934455277.USD","BK4534","LU2361044949.HKD","SG9999014542.SGD","IE00B4R5TH58.HKD","LU2433249047.HKD","LU0985320562.USD","SG9999014567.USD","BK4516","LU0320765489.SGD","BK4533","LU0208291251.USD","LU2106854487.HKD","LU0868494617.USD","LU0965509010.AUD","BK4559","LU1037948897.HKD","SG9999001176.SGD","LU2023250504.SGD","BK1161","LU1585245621.USD","LU1069347547.HKD","LU1291159041.SGD","LU0203345920.USD","IE0002141913.USD","SG9999013999.USD","LU2324357040.USD","LU1934455194.USD","LU0868494708.USD","SGXZ57979304.SGD","LU1116320901.HKD","LU1989772923.USD","LU1571399168.USD","LU2125909247.SGD","BK4550","LU0211331839.USD","LU2125909593.SGD","LU0106261372.USD","LU1066051498.USD","LU0861579265.USD","LU2491050071.SGD","LU1941712348.USD","LU1923622614.USD","SG9999001176.USD","LU0432979614.USD","LU1941712264.USD","IE00BLSP4452.SGD","IE0009355771.USD","IE00BN8TJ469.HKD","LU1201861249.SGD","LU1974910355.USD","LU2361044865.SGD","LU1162221912.USD","LU1093756168.USD","IE00B2B36J28.USD","LU2491050154.USD","SG9999014575.USD","LU0006306889.USD","LU0203347892.USD","LU1989771016.USD","LU1035773651.USD","LU1934455863.HKD","LU2023250843.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU0289739699.SGD","LU1917777945.USD","LU1037948541.HKD","LU1699723380.USD","SG9999002232.USD","BK4585","LU0477156953.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","LU0320765646.SGD","LU1066053197.SGD","002422","LU0965509283.SGD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU1057294990.SGD","IE00BLSP4239.USD","BK4588","IE000M9KFDE8.USD","LU0196878994.USD","LU1061106388.HKD","LU2461242641.AUD","LU1929549753.HKD","LU1066051811.HKD","LU0942090050.USD","LU0965508806.USD","LU2125154935.USD","LU1983299246.USD","LU1989772840.SGD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU2491049909.HKD","LU0098860793.USD","06990","LU1093756325.SGD","LU2125154778.USD","LU1430594728.SGD","SG9999002224.SGD","IE00BJT1NW94.SGD","LU0130102774.USD","LU2089984988.USD","LU0980610538.SGD","LU1023059063.AUD","LU0070302665.USD","LU0122379950.USD","LU0265550946.USD","LU0859254822.USD","BK4007","LU2361045086.USD","LU0266013472.USD","LU2357627491.SGD","LU1116320737.USD","LU2112291526.USD","LU2468319806.SGD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637966332","title":"科伦药业(002422)披露控股股东部分股份质押及解除质押公告,5月21日股价上涨1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637966332","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637966332?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:25","pubTimestamp":1779373521,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,科伦药业报收于32.39元,较前一交易日上涨1.35%,最新总市值为515.25亿元。公告显示,公司控股股东刘革新先生近期办理了部分股份解除质押及新质押业务。本次解除质押股份合计34,190,000股,占公司总股本的2.15%。同时,新增质押股份合计33,540,000股,占公司总股本的2.11%,质押用途为个人资金需求。本次变动后,刘革新先生累计质押股份占其所持股份比例为24.08%,占公司总股本比例为5.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU2148510915.USD","LU1934453819.USD","LU1064130708.USD","LU1979443071.USD","002422","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636839327","title":"科伦药业涨5.58%,东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2636839327","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636839327?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:32","pubTimestamp":1779179573,"startTime":"0","endTime":"0","summary":"今日科伦药业涨5.58%,收盘报32.34元。2026年4月15日,东海证券研究员杜永宏,付婷发布了对科伦药业的研报《公司简评报告:传统主业企稳可期,创新商业化快速推进》,该研报对科伦药业给出“买入”评级。公司输液和中间体及原料药业务有望企稳向上,创新产品快速放量,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为53.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900029120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636752080","title":"科伦药业:公司股份回购计划将严格按照相关规则依规履行实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2636752080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636752080?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:51","pubTimestamp":1779108675,"startTime":"0","endTime":"0","summary":"证券之星消息,科伦药业(002422)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问现在窗口期已经过去了,公司用34.50元的回购价压着一直不回购,是啥意思呢?是怕公司的股价涨高了吗?科伦药业回复:投资者您好,公司股份回购计划将严格按照相关规则依规履行实施。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800034685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","LU2148510915.USD","LU1064131003.USD","BK0060","LU1064130708.USD","BK0239","LU1979443071.USD","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635362271","title":"科伦药业(002422.SZ)子公司SKB118新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2635362271","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635362271?lang=zh_cn&edition=full","pubTime":"2026-05-13 11:45","pubTimestamp":1778643942,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦药业 发布公告,公司近日获悉,公司控股子公司四川科伦博泰生物医药股份有限公司已收到国家药品监督管理局药品审评中心同意程序性细胞死亡蛋白-1x血管内皮生长因子双特异性抗体SKB118新药临床试验申请的临床试验通知书,用于治疗晚期实体瘤。SKB118是一款四价双特异性抗体,目前正开发用于治疗实体瘤。在临床前研究中,SKB118在VEGF存在的情况下显示出提升PD-1的结合和信号阻断能力的协同药理作用,并具有强大的抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934453819.USD","BK0060","LU1064131003.USD","002422","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634491800","title":"科伦药业陷入“三重承压”:旧引擎熄火,新故事难讲,百亿营收保卫战打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2634491800","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634491800?lang=zh_cn&edition=full","pubTime":"2026-05-09 11:38","pubTimestamp":1778297880,"startTime":"0","endTime":"0","summary":"2025年到2026年一季度,科伦药业交出的成绩单,几乎把一家老牌药企能遇到的所有麻烦,都摊在了台面上。 2025年,公司实现营收185.13亿元,同比下滑15.13%;归母净利润17.02亿元,同比下滑42.03%,营收和利润双双跌至近四年低点。2026年一季度,营收进一步降至42.59亿元,归母净利润4.54亿元,经营活动现金流净额明显回落,应收账款已接近50亿元。以下,我们从三大业务板块切入,拆解科伦当前最核心的风险与问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-05-09/doc-inhxhkfi6928480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131100","title":"科伦药业(002422)披露回购股份价格上限调整公告,5月6日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131100","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131100?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:18","pubTimestamp":1778077100,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,科伦药业报收于34.01元,较前一交易日下跌1.62%,最新总市值为541.02亿元。近日,科伦药业发布《关于回购公司股份进展的公告》。公告显示,公司于2026年1月4日审议通过回购股份方案,拟通过集中竞价方式回购股份;回购价格上限由35元/股调整为34.53元/股,自2026年5月11日起生效;回购资金总额不低于5,000万元且不超过10,000万元。本次回购符合相关法规及既定方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","LU1979443071.USD","LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","LU1934453819.USD","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631859485","title":"科伦药业(002422)披露控股股东部分股份质押及解除质押公告,4月29日股价上涨4.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631859485","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631859485?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:16","pubTimestamp":1777457777,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘,科伦药业报收于34.1元,较前一交易日上涨4.6%,最新总市值为544.94亿元。公告显示,控股股东刘革新先生近日办理了部分股份解除质押及新质押业务。本次解除质押13,300,000股,占其所持股份比例3.51%,占公司总股本0.83%。同时,新增质押12,200,000股,占其所持股份比例3.22%,占公司总股本0.77%,质押用途为个人资金需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900057975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","BK0239","002422","LU1064130708.USD","LU1064131003.USD","BK0060","LU2148510915.USD","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631001531","title":"图解科伦药业一季报:第一季度单季净利润同比下降22.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631001531","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631001531?lang=zh_cn&edition=full","pubTime":"2026-04-29 05:31","pubTimestamp":1777411900,"startTime":"0","endTime":"0","summary":"证券之星消息,科伦药业2026年一季报显示,一季度公司主营收入42.59亿元,同比下降2.98%;归母净利润4.54亿元,同比下降22.34%;扣非净利润3.81亿元,同比下降32.42%;负债率27.7%,投资收益6293.01万元,财务费用1170.79万元,毛利率45.31%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900012405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745559","title":"科伦药业:公司持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745559?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:00","pubTimestamp":1776675628,"startTime":"0","endTime":"0","summary":"证券之星消息,科伦药业(002422)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司是持有普利制药股票还是债券?谢谢科伦药业回复:投资者您好,公司持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000022697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","002422","BK1574","LU2148510915.USD","LU1064130708.USD","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628243894","title":"股市必读:科伦药业(002422)4月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628243894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628243894?lang=zh_cn&edition=full","pubTime":"2026-04-17 02:14","pubTimestamp":1776363251,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘,科伦药业报收于35.92元,上涨0.62%,换手率1.57%,成交量20.51万手,成交额7.32亿元。董秘最新回复投资者: 董秘您好,麻烦告知公司截至2026年4月10日的股东总户数,谢谢。投资者: 最新股东数董秘: 投资者您好,2026年3月31日公司普通股股东总数为41,048户。当日关注点来自交易信息汇总:4月16日主力资金与游资资金均呈净流入态势,合计净流入超4000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700003174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","BK0060","LU1064131003.USD","002422","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627288322","title":"科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2627288322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627288322?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:39","pubTimestamp":1776245949,"startTime":"0","endTime":"0","summary":"证券之星消息,科伦药业(002422)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司持有2000多万的普利制药,都已经退市了 ,为什么还高位买进科伦药业回复:投资者您好,公司出于战略目的而计划长期持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU1979443071.USD","01477","LU1064130708.USD","LU1064131003.USD","BK1574","BK0239","BK0060","LU2148510915.USD","002422","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627145741","title":"股市必读:科伦药业(002422)4月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2627145741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627145741?lang=zh_cn&edition=full","pubTime":"2026-04-14 00:57","pubTimestamp":1776099429,"startTime":"0","endTime":"0","summary":"截至2026年4月13日收盘,科伦药业报收于34.67元,上涨1.97%,换手率1.46%,成交量19.01万手,成交额6.57亿元。科伦有能力研发出好的产品但不会卖也没用啊董秘: 投资者您好,感谢您对公司的关注与建议。当日关注点来自交易信息汇总:4月13日主力资金净流入97.76万元,游资积极介入,散户资金呈净流出态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400000733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","002422","LU1064131003.USD","BK0239","LU1934453819.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626184545","title":"4月9日科伦药业发布公告,股东减持318.21万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626184545","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626184545?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:01","pubTimestamp":1775736112,"startTime":"0","endTime":"0","summary":"证券之星消息,4月9日科伦药业发布公告《科伦药业:关于持股5%以上股东减持股份触及1%整数倍的公告》,其股东雅安市国有资产经营有限责任公司于2026年3月10日至2026年4月8日间合计减持318.21万股,占公司目前总股本的0.1991%,变动期间该股股价上涨8.56%,截止4月8日收盘报34.63元。股东增减持详情见下表:根据科伦药业2025年年报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900034357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","LU1064130708.USD","002422","LU2148510915.USD","LU1934453819.USD","BK0060","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901599","title":"科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901599","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626901599?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:29","pubTimestamp":1775719740,"startTime":"0","endTime":"0","summary":" 近日,科伦药业披露2025年年度报告。作为国内输液与抗生素中间体龙头,科伦药业2025年的经营态势却较为严峻,传统业务稳健托底、创新业务逐步蓄力的增长逻辑正面临挑战。从财务数据看,公司营收、净利润双双大幅下滑,盈利指标持续恶化,现金流同步缩水,多重风险集中显现。 2025年,科伦药业核心财务指标全线转向。 综上,2025年是科伦药业压力集中释放的一年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-09/doc-inhtwtex8839730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002422","LU1934453819.USD","LU2148510915.USD","BK0060","BK0239","LU1064131003.USD","LU1979443071.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779785345272,"stockEarnings":[{"period":"1week","weight":0.1218},{"period":"1month","weight":0.027},{"period":"3month","weight":0.124},{"period":"6month","weight":0.0074},{"period":"1year","weight":-0.0999},{"period":"ytd","weight":0.1872}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.0085},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2402},{"period":"ytd","weight":0.0463}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41048人(较上一季度减少6.85%)","perCapita":"31636股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159078万元","survey":" 四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}